The oligonucleotide synthesis, modification and purification services market is projected to grow at

Roots Analysis has done a detailed study on “Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 300+ page report, which features 140+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html

Key Market Insights

• More than 80 companies currently claim to offer manufacturing related services, at different scales of operations, for a variety of oligonucleotide-based products
• A wide range of services related to the synthesis, modification and purification of oligonucleotides, are currently offered within a fragmented service provider landscape that is mostly concentrated in the developed geographies
• In order to cater to the growing needs of clients / sponsors, companies have established presence across different regions; the US and some European nations have emerged as current hubs for oligonucleotide production
• Players involved in this domain are steadily expanding their capabilities in order to enhance their respective service portfolios and thereby, achieve an edge over competing firms
• Service providers are actively investing in expansion projects to upgrade existing capabilities and capacity; several partnerships, mostly focused on offering manufacturing and supply services, have been forged
• Over the past few years, more than 270 trials of oligonucleotide-based interventions, across various phases of development and to treat a diverse range of diseases, have been registered across different centers worldwide
• Most of the global, annual oligonucleotide manufacturing capacity belongs to established service providers, accounting for over 80% of available capacity across various geographies
• The demand for manufacturing of oligonucleotide-based products is expected to increase in the coming years; we believe that the stakeholders may have to expand their respective capacities to ensure consistent supply
• We expect oligonucleotide-based drug developers to continue to outsource their manufacturing operations in the short to mid-term; service-based revenues are estimated to grow at an annualized rate of more than 10%
• In the long-term, the projected opportunity is anticipated to be well distributed across various therapeutic areas, scales of operation and across companies of different sizes

For more information, please visit https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html

Table of Contents

1.         PREFACE

1.1.      Scope of the Report

1.2.      Research Methodology

1.3.      Chapter Outlines

2.         EXECUTIVE SUMMARY

3.         INTRODUCTION

3.1.      Context and Background

3.2.      Overview of Oligonucleotide-based Products

3.3.      Types of Oligonucleotides

3.3.1.    Antisense Oligonucleotides

3.3.2.    Aptamers

3.3.3.    miRNA